BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:MK-8690 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of MK-8690\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07895524-75@assetmemo.bio
DTSTAMP:20261121T004048Z
DTSTART;VALUE=DATE:20271019
DTEND;VALUE=DATE:20271020
SUMMARY:MK-8690: Phase 2 readout est. (NCT07895524)
DESCRIPTION:MK-8690\, phase 2\, Rheumatoid Arthritis.\nStudy: A Clinical Tr
 ial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004)\nEs
 timated primary completion: 19 October 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/mk-8690#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07895524
URL:https://assetmemo.bio/drug/mk-8690#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07463183-75@assetmemo.bio
DTSTAMP:20261121T004048Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:MK-8690: Phase 2 readout est. (NCT07463183)
DESCRIPTION:MK-8690\, phase 2\, Ulcerative Colitis.\nStudy: A Study to Eval
 uate Efficacy and Safety of MK-8690 in Participants With Moderately to Sev
 erely Active Ulcerative Colitis (MK-8690-002)\nEstimated primary completio
 n: 28 October 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/m
 k-8690#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07463183
URL:https://assetmemo.bio/drug/mk-8690#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
